Austin, TX – According to filings with the U.S. Securities and Exchange Commission, TFF Pharmaceuticals is raising $8,170,000.00 in a new round of investment. Sources indicate as part of senior management Chief Financial Officer, Kirk Coleman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TFF Pharmaceuticals

TFF Pharmaceuticals can generate dry powder inhaler versions of these drugs using nothing but the drug itself and approved lung friendly ingredients. This means that drugs of all types small molecules, biologics, even combinations can be dosed directly to the lungs with few, if any, side effects.

To learn more about TFF Pharmaceuticals, visit http://tffpharma.com/

Contact:
Kirk Coleman, Chief Financial Officer
737-802-1979

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved